ArticleInternational journal of molecular medicine2017
Distal-less homeobox 5 is a master regulator of the osteogenesis of human mesenchymal stem cells.
Article in International journal of molecular medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 42 citations in OpenAlex.
- Triphenyl phosphate promotes lipid accumulation in human mesenchymal stem cells through metabolic stress pathways.Archives of toxicology · 2026Article
- Metallic topological structures in bone repair implants: Design, properties, and biological interactions.Journal of orthopaedic translation · 2026Review
- Review
- Polydactyly bone marrow-derived mesenchymal stem cell-conditioned medium can prevent cartilage degeneration and alleviate knee pain in a rat model of osteoarthritis.Regenerative therapy · 2025Article
- Targeting Msx2 as a brake in the fusion fate of osteoclasts and an anabolic therapy in pre-clinical models of osteoporosis.Nature communications · 2025Article
- Reducing Healing Period with DDM/rhBMP-2 Grafting for Early Loading in Dental Implant Surgery.Tissue engineering and regenerative medicine · 2025Article
- Pharmacological impacts of tanshinone on osteogenesis and osteoclastogenesis: a review.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- RNA-binding proteins in bone pathophysiology.Frontiers in cell and developmental biology · 2024Review
- Osteogenic Differentiation Potential of Mesenchymal Stem Cells Using Single Cell Multiomic Analysis.Genes · 2023Article
- DLX5 promotesGenes & diseases · 2023Article
- Peonidin-3-Nutrients · 2023Article
- Downregulation of the RNA-binding protein PUM2 facilitates MSC-driven bone regeneration and prevents OVX-induced bone loss.Journal of biomedical science · 2023Article
- Fabrication of Solvent-Free PCL/β-TCP Composite Fiber for 3D Printing: Physiochemical and Biological Investigation.Polymers · 2023Article
- A bioactive material with dual integrin-targeting ligands regulates specific endogenous cell adhesion and promotes vascularized bone regeneration in adult and fetal bone defects.Bioactive materials · 2023Article
- Purified regenerating retinal neurons reveal regulatory role of DNA methylation-mediated Na+/K+-ATPase in murine axon regeneration.Communications biology · 2023Article
- Long non-coding RNA CASC2 regulates osteoblasts matrix mineralization.Frontiers in bioengineering and biotechnology · 2023Article
- Epigenetic Regulation of NGF-Mediated Osteogenic Differentiation in Human Dental Mesenchymal Stem Cells.Stem cells (Dayton, Ohio) · 2022Article
- Therapeutic Treatments for Osteoporosis-Which Combination of Pills Is the Best among the Bad?International journal of molecular sciences · 2022Review
- Inhibition of Osteoblast Differentiation by JAK2Frontiers in oncology · 2022Article
- Activation of bivalent factor DLX5 cooperates with master regulator TP63 to promote squamous cell carcinoma.Nucleic acids research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesenchymal stem cells (MSCs) differentiate into multiple lineages and are a promising source of cells for clinical use. Previously, we found that the gene distal‑less homeobox 5 (DLX5) is specifically expressed in MSCs with osteogenic potential. Understanding the mechanism of osteogenesis is necessary for successful bone regeneration using MSCs. The aim of this study was to examine the function of the DLX5 gene in MSCs during osteogenesis (bone development). We analyzed the possible association between DLX5 expression and osteogenesis-, chondrogenesis- and adipogenesis-related gene expression in different cells isolated from bone marrow and cord blood. Differentiation capacity was assessed by observing morphological changes, monitoring gene expression patterns, and staining with Von Kossa, safranin O, and Oil Red O. Suppression of DLX5 expression by means of a small interfering RNA (siRNA) downregulated osteogenic markers and reduced the signs of calcium mineralization. Tanshinone IIA is a known small molecule activator of bone morphogenetic protein (BMP) signaling. Here, we report that induction of DLX5 by tanshinone IIA in MSCs enhanced osteogenic differentiation. In addition, we showed that tanshinone IIA (as a mediator of BMP2 signaling) activates runt-related transcription factor 2 (RUNX2) in MSCs and initiates calcium mineralization during osteogenesis. Taken together, these findings indicate that, in MSCs, DLX5 is a master regulator of osteogenesis. Furthermore, tanshinone IIA may be valuable for stem cell-based therapies of certain bone diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.